Oyster Point Pharma, Inc.

OYST

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
OC-01 (varenicline) nasal spray	Phase 3	Dry Eye Disease (DED)	-
OC-01 Low Dose, 0.12 mg/mL	Phase 3	Long Term Follow up Dry Eye Disease	-
OC-02 (simpinicline) nasal spray	Phase 2	Dry Eye Disease	-
OC-01 (varenicline) nasal spray 1.2 mg/ml	Phase 2	Neurotrophic Keratopathy	-
OC-01 0.1% 0.6 mg/ml	Phase 2	Dry Eye Disease	-
Placebo (vehicle control) nasal spray	Phase 2	Dry Eye Disease	-
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)	Phase 2	Dry Eye Disease	-
Placebo (vehicle) nasal spray	Phase 2	Dry Eye Disease	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

OYST News